Metformin
- Generic Name
- Metformin
- Brand Names
- Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11N5
- CAS Number
- 657-24-9
- Unique Ingredient Identifier
- 9100L32L2N
- Background
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.
Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.
- Indication
Metformin immediate-release formulations
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.
Metformin extended-release tablet (XR)
The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.
Metformin combination products
Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- -
Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II Diabetes
- Conditions
- DyslipidemiaType II Diabetes
- Interventions
- First Posted Date
- 2015-10-26
- Last Posted Date
- 2018-10-03
- Lead Sponsor
- Yuhan Corporation
- Target Recruit Count
- 249
- Registration Number
- NCT02586129
- Locations
- 🇰🇷
Seoul National Universitiy Bundang Hospital, Seongnam-Si, Gyeonggi-Do, Korea, Republic of
Impact of OCT1 on Metformin Tolerance
- First Posted Date
- 2015-10-26
- Last Posted Date
- 2018-06-13
- Lead Sponsor
- NHS Tayside
- Target Recruit Count
- 61
- Registration Number
- NCT02586636
- Locations
- 🇬🇧
Ninewells Hospital, Dundee, Angus, United Kingdom
Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion
- Conditions
- ErythroplakiaOral Cavity CarcinomaOral LeukoplakiaHyperplasia
- Interventions
- Other: Laboratory Biomarker AnalysisDrug: Metformin Hydrochloride
- First Posted Date
- 2015-10-20
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 26
- Registration Number
- NCT02581137
- Locations
- 🇺🇸
UC San Diego Medical Center - Hillcrest, San Diego, California, United States
🇨🇦BC Cancer Research Centre, Vancouver, British Columbia, Canada
🇺🇸University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
Demonstrate Bioequivalence of Two 12.5 mg Empagliflozin/500 mg Metformin Fixed Dose Combination Tablets With Free Combination of Empagliflozin 25 mg and Metformin 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions
- First Posted Date
- 2015-10-16
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 25
- Registration Number
- NCT02577315
- Locations
- 🇷🇺
1276.27.001 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation
DDI (Effect of Metformin and Furosemide on Rosuvastatin PK)
- First Posted Date
- 2015-10-14
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18
- Registration Number
- NCT02574845
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
Continuation of Metformin to Improve And Keep Peri-operative Glycemic Control
- First Posted Date
- 2015-10-08
- Last Posted Date
- 2021-10-08
- Lead Sponsor
- McMaster University
- Registration Number
- NCT02571608
Metformin for Preventing Frailty in High-risk Older Adults
- First Posted Date
- 2015-10-07
- Last Posted Date
- 2024-03-04
- Target Recruit Count
- 145
- Registration Number
- NCT02570672
- Locations
- 🇺🇸
University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
The Effect of Metformin on Different Hormones in PCOS Patients
- First Posted Date
- 2015-10-06
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Ahmed Maged
- Target Recruit Count
- 48
- Registration Number
- NCT02568488
A Drug-drug Interaction Study Between Daclatasvir and Metformin
- Conditions
- Hepatitis CDiabetes MellitusInsulin Resistance
- Interventions
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2020-12-07
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT02565862
- Locations
- 🇳🇱
CRCN, Radboud University Medical Center, Nijmegen, Netherlands
Metformin Improves Clinical Pregnancy Rate in Polycystic Ovarian Syndrome Patients
- Conditions
- Reproductive EndocrinologyPolycystic Ovarian Syndrome
- Interventions
- First Posted Date
- 2015-09-29
- Last Posted Date
- 2020-08-12
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 66
- Registration Number
- NCT02562664
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.